StockNews.com Initiates Coverage on Cara Therapeutics (NASDAQ:CARA)

StockNews.com started coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research note issued to investors on Friday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Price Performance

The business’s 50-day moving average price is $15.19 and its two-hundred day moving average price is $13.17. Cara Therapeutics has a twelve month low of $8.13 and a twelve month high of $29.98. The stock has a market capitalization of $24.33 million, a P/E ratio of -0.25 and a beta of 0.41.

Institutional Investors Weigh In On Cara Therapeutics

Several hedge funds have recently modified their holdings of CARA. Curi RMB Capital LLC purchased a new position in shares of Cara Therapeutics in the 4th quarter valued at about $277,000. Shay Capital LLC acquired a new stake in Cara Therapeutics in the fourth quarter valued at approximately $524,000. Finally, Rockefeller Capital Management L.P. acquired a new stake in Cara Therapeutics in the fourth quarter valued at approximately $953,000. 44.66% of the stock is owned by hedge funds and other institutional investors.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.